DK1766077T3 - Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse - Google Patents
Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelseInfo
- Publication number
- DK1766077T3 DK1766077T3 DK05762518.8T DK05762518T DK1766077T3 DK 1766077 T3 DK1766077 T3 DK 1766077T3 DK 05762518 T DK05762518 T DK 05762518T DK 1766077 T3 DK1766077 T3 DK 1766077T3
- Authority
- DK
- Denmark
- Prior art keywords
- disorder
- pathways
- differentially expressed
- expressed genes
- severe depressive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/304—Mood disorders, e.g. bipolar, depression
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58199804P | 2004-06-21 | 2004-06-21 | |
| US62125204P | 2004-10-22 | 2004-10-22 | |
| US66729605P | 2005-03-31 | 2005-03-31 | |
| PCT/US2005/022111 WO2006002262A2 (en) | 2004-06-21 | 2005-06-21 | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1766077T3 true DK1766077T3 (da) | 2012-07-16 |
Family
ID=35782328
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05762518.8T DK1766077T3 (da) | 2004-06-21 | 2005-06-21 | Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse |
| DK11175854.6T DK2453024T3 (da) | 2004-06-21 | 2005-06-21 | Gener og ledningsveje, der eksprimeres forskelligt i bipolar lidelse og/eller større depressiv lidelse |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11175854.6T DK2453024T3 (da) | 2004-06-21 | 2005-06-21 | Gener og ledningsveje, der eksprimeres forskelligt i bipolar lidelse og/eller større depressiv lidelse |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8415298B2 (da) |
| EP (2) | EP2453024B1 (da) |
| AT (1) | ATE551432T1 (da) |
| AU (1) | AU2005258161B2 (da) |
| CA (1) | CA2571243A1 (da) |
| DK (2) | DK1766077T3 (da) |
| ES (1) | ES2660765T3 (da) |
| WO (1) | WO2006002262A2 (da) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003291720A1 (en) * | 2002-11-01 | 2004-06-18 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for diagnosing and treating mood disorders |
| DK1766077T3 (da) | 2004-06-21 | 2012-07-16 | Univ Leland Stanford Junior | Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse |
| EP1951908B1 (en) * | 2005-11-12 | 2013-08-07 | The Board of Trustees of The Leland Stanford Junior University | Fgf2-related methods for diagnosing and treating depression |
| US8163475B2 (en) * | 2006-05-18 | 2012-04-24 | The Mclean Hospital Corporation | Methods for diagnosis and prognosis of psychotic disorders |
| US20100256001A1 (en) * | 2007-04-03 | 2010-10-07 | The Scripps Research Institute | Blood biomarkers for mood disorders |
| US20100248230A1 (en) * | 2007-04-14 | 2010-09-30 | Schlaak Joerg Friedrich | Novel medical diagnostic method and therapy in the context of interfreon-stimulated genes that induce depression |
| WO2008144371A1 (en) * | 2007-05-16 | 2008-11-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for diagnosing suicidal tendencies |
| WO2009011911A2 (en) * | 2007-07-18 | 2009-01-22 | The Johns Hopkins University | Methods of detecting prostate cancer |
| US7973019B1 (en) * | 2007-10-03 | 2011-07-05 | Alcon Research, Ltd. | Transferrin/transferrin receptor-mediated siRNA delivery |
| WO2009059316A1 (en) * | 2007-11-02 | 2009-05-07 | The Board Of Trustees Of The Leland Stanford Junior University | Fgf9-related methods for treating anxiety |
| EP2570501A3 (en) * | 2008-01-02 | 2013-04-10 | Suregene Llc | Genetic markers of mental illness |
| FR2929292A1 (fr) * | 2008-03-28 | 2009-10-02 | Exonhit Therapeutics S A Sa | Procede et methodes de diagnostic de la maladie d'alzheimer |
| GB0808832D0 (en) * | 2008-05-15 | 2008-06-18 | Ge Healthcare Ltd | Biomarkers for depression |
| GB0808834D0 (en) * | 2008-05-15 | 2008-06-18 | Ge Healthcare Ltd | Biomarkers for depression |
| WO2009154697A2 (en) | 2008-05-28 | 2009-12-23 | Massachusetts Institute Of Technology | Disc-1 pathway activators in the control of neurogenesis |
| CN102224256A (zh) * | 2008-08-27 | 2011-10-19 | H.隆德贝克有限公司 | 用于测量生物标记概况的系统和方法 |
| EP2963129A3 (en) * | 2008-11-12 | 2016-05-11 | University of Utah Research Foundation | Autism associated genetic markers |
| US20110311512A1 (en) * | 2008-11-14 | 2011-12-22 | Hakon Hakonarson | Genetic Variants Underlying Human Cognition and Methods of Use Thereof as Diagnostic and Therapeutic Targets |
| US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
| GB201204816D0 (en) * | 2012-03-19 | 2012-05-02 | Brainco Biopharma S L | Transgenic animal model of mood disorders |
| WO2014133707A1 (en) * | 2013-03-01 | 2014-09-04 | Psychnostics, Llc | Genes expressed in mental illness and mood disorders |
| WO2014159720A1 (en) * | 2013-03-13 | 2014-10-02 | The University Of Chicago | Methods and compositions for inhibiting glyoxalase 1 (glo1) |
| WO2015027116A1 (en) * | 2013-08-21 | 2015-02-26 | The Regents Of The University Of California | Diagnostic and predictive metabolite patterns for disorders affecting the brain and nervous system |
| WO2015129324A1 (ja) * | 2014-02-26 | 2015-09-03 | 国立大学法人徳島大学 | 精神疾患マーカーおよびその用途 |
| CN109022486B (zh) * | 2018-09-20 | 2021-09-07 | 河北医科大学第二医院 | 一种癫痫动物模型的构建方法 |
| EP3819387A1 (en) * | 2019-11-08 | 2021-05-12 | Alcediag | Differential diagnosis of bipolar disorder and unipolar depression by blood rna editing biomarkers |
| CN111621525B (zh) * | 2020-06-18 | 2021-04-23 | 中赛干细胞基因工程有限公司 | Stx1b基因在促进人脂肪间充质干细胞生长和分化中的用途 |
| WO2022109165A1 (en) * | 2020-11-18 | 2022-05-27 | Indiana University Research And Technology Corporation | Methods for objective assessment, risk prediction, matching to existing medications and new methods of using drugs, and monitoring responses to treatments for mood disorders |
| CN116904578B (zh) * | 2023-07-21 | 2024-03-15 | 武汉市精神卫生中心 | 线粒体差异化表达特征基因在制备重度抑郁症诊断剂中的应用 |
| WO2025183250A1 (ko) * | 2024-02-29 | 2025-09-04 | 주식회사 비욘드디엑스 | 우울증과 양극성 장애 구분용 바이오마커 및 이의 용도 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
| US4405712A (en) | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
| US4673641A (en) | 1982-12-16 | 1987-06-16 | Molecular Genetics Research And Development Limited Partnership | Co-aggregate purification of proteins |
| GB8424757D0 (en) | 1984-10-01 | 1984-11-07 | Pasteur Institut | Retroviral vector |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
| US5554386A (en) | 1986-07-03 | 1996-09-10 | Advanced Magnetics, Inc. | Delivery of therapeutic agents to receptors using polysaccharides |
| US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
| US6187752B1 (en) | 1988-03-07 | 2001-02-13 | E.R. Squibb & Sons, Inc. | Method for treating schizophrenia employing an ace inhibitor |
| US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5624898A (en) | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
| US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| CA2092323A1 (en) | 1990-10-01 | 1992-04-02 | George Y. Wu | Targeting viruses and cells for selective internalization by cells |
| EP0556345B2 (en) | 1990-10-31 | 2005-10-12 | Cell Genesys, Inc. | Retroviral vectors useful for gene therapy |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5521291A (en) | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
| WO1993014188A1 (en) | 1992-01-17 | 1993-07-22 | The Regents Of The University Of Michigan | Targeted virus |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| DE69333434T2 (de) | 1992-04-03 | 2005-03-03 | The Regents Of The University Of California, Oakland | Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid |
| CA2133411A1 (en) | 1992-04-03 | 1993-10-14 | Alexander T. YOUNG | Gene therapy using targeted viral vectors |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| US5656609A (en) | 1992-09-24 | 1997-08-12 | University Of Connecticut | Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine |
| WO1994006923A1 (en) | 1992-09-24 | 1994-03-31 | The University Of Connecticut | Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells |
| ES2061380B1 (es) | 1992-11-23 | 1995-07-01 | Boehringer Ingelheim Espana | Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores. |
| US5346701A (en) | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
| US5578475A (en) | 1993-07-12 | 1996-11-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
| EP2423322A1 (en) | 1993-11-12 | 2012-02-29 | PHRI Properties, Inc. | Hybridization probes for nucleic acid detection, universal stems, methods and kits |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5593853A (en) | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
| US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
| FR2718150B1 (fr) | 1994-03-29 | 1996-04-26 | Rhone Poulenc Rorer Sa | Virus recombinants, préparation et utilisation en thérapie génique. |
| US20030191061A1 (en) | 1994-03-31 | 2003-10-09 | Brewitt Barbara A. | Treatment methods using homeopathic preparations of growth factors |
| US6024734A (en) * | 1994-03-31 | 2000-02-15 | Brewitt; Barbara A. | Treatment methods using homeopathic preparations of growth factors |
| US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
| US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
| IL122473A (en) | 1995-06-12 | 2003-11-23 | Yeda Res & Dev | Fgfr3 as a marker for mesenchymal skeletal progenitor cells |
| US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
| IL124967A (en) | 1995-12-18 | 2000-07-26 | Univ Washington | Method for nucleic acid analysis using fluorescence resonance energy transfer |
| DE69723429T3 (de) * | 1996-03-22 | 2007-09-20 | Curis, Inc., Cambridge | Verfahren zur verbesserten funktionellen Erholung der motorischen Koordination, der Sprache oder Sinneswahrnehmung nach Trauma oder Ischämie des ZNS |
| US6117890A (en) | 1996-08-01 | 2000-09-12 | Eli Lilly And Company | Method for treating bipolar disorder |
| JP2001506580A (ja) | 1996-12-24 | 2001-05-22 | 藤沢薬品工業株式会社 | アミノピペラジン誘導体の新規用途 |
| EP1009403A4 (en) | 1997-04-11 | 2002-08-28 | Lilly Co Eli | METHOD FOR TREATING SCHIZOPHRENIA |
| WO1998053820A1 (en) | 1997-05-29 | 1998-12-03 | H. Lundbeck A/S | Treatment of schizophrenia and psychosis |
| CA2216686A1 (en) | 1997-09-24 | 1999-03-24 | Guy A. Rouleau | Allelic variants of the phospholipase c-gamma1 gene associated with bipolar disorder |
| CA2306817A1 (en) | 1997-10-27 | 1999-05-06 | Cortex Pharmaceuticals Inc. | Treatment of schizophrenia with ampakines and neuroleptics |
| NZ507981A (en) | 1998-05-29 | 2003-10-31 | Lilly Co Eli | Combination therapy for treatment of bipolar disorders |
| US6232326B1 (en) | 1998-07-14 | 2001-05-15 | Jodi A. Nelson | Treatment for schizophrenia and other dopamine system dysfunctions |
| US7273618B2 (en) * | 1998-12-09 | 2007-09-25 | Chiron Corporation | Method for administering agents to the central nervous system |
| AUPP810399A0 (en) | 1999-01-11 | 1999-02-04 | Unisearch Limited | Catalytic molecules |
| EP1165836A2 (en) | 1999-03-30 | 2002-01-02 | Genset | Schizophrenia associated genes, proteins and biallelic markers |
| US7410941B1 (en) | 1999-04-13 | 2008-08-12 | The Kenneth S. Warren Institute, Inc. | Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin |
| US6239162B1 (en) | 1999-05-17 | 2001-05-29 | St. Elizabeth's Medical Center | Method for treating depression |
| EP1410036A2 (en) | 2001-01-19 | 2004-04-21 | Mindsense Biosystems Ltd. | Methods and compositions for diagnosing and treating a subject having depression |
| EP1233075A3 (en) | 2001-02-15 | 2003-01-08 | Whitehead Institute For Biomedical Research | BDNF polymorphism and association with bipolar disorder |
| US20030008820A1 (en) | 2001-03-27 | 2003-01-09 | Massachusetts Institute Of Technology | Methods and products related to FGF dimerization |
| US20030166555A1 (en) | 2001-04-02 | 2003-09-04 | Alberini Cristina M. | Methods and compositions for regulating memory consolidation |
| US20020169102A1 (en) | 2001-04-03 | 2002-11-14 | Frey William H. | Intranasal delivery of agents for regulating development of implanted cells in the CNS |
| WO2002083877A1 (en) | 2001-04-11 | 2002-10-24 | Stem Cell Therapeutics Inc. | Production of tyrosine hydroxylase positive neurons |
| US20030096264A1 (en) | 2001-06-18 | 2003-05-22 | Psychiatric Genomics, Inc. | Multi-parameter high throughput screening assays (MPHTS) |
| US20030152972A1 (en) | 2001-11-08 | 2003-08-14 | Whitehead Institute For Biomedical Research | Gene expression associated with psychiatric disorders |
| WO2003039490A2 (en) | 2001-11-09 | 2003-05-15 | Office Of Technology Licensing Stanford University | Compositions and methods for diagnosing and treating mental disorders |
| US20040152107A1 (en) | 2002-09-18 | 2004-08-05 | C. Anthony Altar | Gene signature of electroshock therapy and methods of use |
| AU2003291720A1 (en) * | 2002-11-01 | 2004-06-18 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for diagnosing and treating mood disorders |
| MXPA05005022A (es) * | 2002-11-14 | 2005-08-03 | Wyeth Corp | Metodos y composiciones para tratar trastornos neurologicos. |
| CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| DE602004027508D1 (de) | 2003-08-07 | 2010-07-15 | Enkam Pharmaceuticals As | Lpa-haltige verbindungen |
| US20050209181A1 (en) | 2003-11-05 | 2005-09-22 | Huda Akil | Compositions and methods for diagnosing and treating mental disorders |
| JP2005312435A (ja) | 2004-03-29 | 2005-11-10 | Kazuhito Rokutan | うつ病の評価方法 |
| DK1766077T3 (da) | 2004-06-21 | 2012-07-16 | Univ Leland Stanford Junior | Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse |
| EP1951908B1 (en) | 2005-11-12 | 2013-08-07 | The Board of Trustees of The Leland Stanford Junior University | Fgf2-related methods for diagnosing and treating depression |
| WO2009059316A1 (en) | 2007-11-02 | 2009-05-07 | The Board Of Trustees Of The Leland Stanford Junior University | Fgf9-related methods for treating anxiety |
| TWI552751B (zh) | 2011-06-20 | 2016-10-11 | Ｈ 朗德貝克公司 | 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法 |
-
2005
- 2005-06-21 DK DK05762518.8T patent/DK1766077T3/da active
- 2005-06-21 AT AT05762518T patent/ATE551432T1/de active
- 2005-06-21 EP EP11175854.6A patent/EP2453024B1/en not_active Expired - Lifetime
- 2005-06-21 CA CA002571243A patent/CA2571243A1/en not_active Abandoned
- 2005-06-21 WO PCT/US2005/022111 patent/WO2006002262A2/en not_active Ceased
- 2005-06-21 EP EP05762518A patent/EP1766077B1/en not_active Expired - Lifetime
- 2005-06-21 ES ES11175854.6T patent/ES2660765T3/es not_active Expired - Lifetime
- 2005-06-21 US US11/158,530 patent/US8415298B2/en not_active Expired - Fee Related
- 2005-06-21 AU AU2005258161A patent/AU2005258161B2/en not_active Ceased
- 2005-06-21 DK DK11175854.6T patent/DK2453024T3/da active
-
2013
- 2013-02-25 US US13/776,647 patent/US9486499B2/en not_active Expired - Fee Related
-
2016
- 2016-09-20 US US15/270,193 patent/US9957568B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1766077A4 (en) | 2008-02-13 |
| US20140073568A1 (en) | 2014-03-13 |
| US9957568B2 (en) | 2018-05-01 |
| ES2660765T3 (es) | 2018-03-26 |
| ATE551432T1 (de) | 2012-04-15 |
| WO2006002262A2 (en) | 2006-01-05 |
| EP2453024B1 (en) | 2017-12-06 |
| AU2005258161A1 (en) | 2006-01-05 |
| EP1766077A2 (en) | 2007-03-28 |
| US20060051786A1 (en) | 2006-03-09 |
| EP2453024A2 (en) | 2012-05-16 |
| US9486499B2 (en) | 2016-11-08 |
| CA2571243A1 (en) | 2006-01-05 |
| AU2005258161B2 (en) | 2011-05-26 |
| EP1766077B1 (en) | 2012-03-28 |
| EP2453024A3 (en) | 2012-08-15 |
| US20170211144A1 (en) | 2017-07-27 |
| US8415298B2 (en) | 2013-04-09 |
| WO2006002262A3 (en) | 2007-06-14 |
| DK2453024T3 (da) | 2018-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2453024A3 (en) | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder | |
| WO2006105516A3 (en) | Compositions and methods for diagnosing and treating neuropsychiatric disorders | |
| EA201071245A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс | |
| CY1109985T1 (el) | Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων | |
| TW200517114A (en) | Methods and reagents for the treatment of immunoinflammatory disorders | |
| CY1117030T1 (el) | Τροποποιηση της εκφρασης απολιποπρωτεϊνης c-iii | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| ATE540129T1 (de) | Target zur therapie kognitiver behinderungen | |
| NO20082473L (no) | Fremgangsmater, sammensetninger og sett for behandling av medisinske tilstander | |
| EA201000644A1 (ru) | Антитела для лечения и профилактики болезни альцгеймера и их применение | |
| IL187343A0 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| BRPI0607307A2 (pt) | compostos e composições como inibidores de proteìna cinase | |
| EA200970891A1 (ru) | Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы | |
| NO20083877L (no) | Sammensetninger og fremgangsmater for behandling av immunoinflammatoriske forstyrrelser | |
| WO2006063704A3 (en) | Single nucleotide polymorphism (snp) associated to type ii diabetes | |
| ATE472998T1 (de) | Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis | |
| WO2007060471A3 (en) | Biomarkers and methods for identification of agents useful in the treatment of affective disorders | |
| IL166466A0 (en) | Methods for the treatment of dementia based on apoe genotype | |
| ATE454465T1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
| WO2004047727A3 (en) | Compositions and methods for diagnosing and treating mood disorders | |
| WO2008091873A3 (en) | Compositions and methods for the identification, assessment, prevention and therapy of thymic lymphoma or hamartomatous tumours | |
| DE602005007220D1 (de) | Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs | |
| ATE511401T1 (de) | Kombinierte gentherapie zur behandlung makroskopischer glioma | |
| DE602004001047D1 (de) | Phospholipidester von Clofarabin | |
| AR039803A1 (es) | Proteinas 1 y 2 relacionadas con el receptor ldl y tratamiento de los trastornos de huesos o cartilago |